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The transcription factor NF-ŒB is a master regulator of the
innate immune response and plays a central role in inflamma-
tory diseases by mediating the expression of pro-inflammatory
cytokines. Ubiquitination-triggered proteasomal degradation of
DNA-bound NF-ŒB strongly limits the expression of its target
genes. Conversely, USP7 (deubiquitinase ubiquitin-specific
peptidase 7) opposes the activities of E3 ligases, stabilizes DNA-
bound NF-ŒB, and thereby promotes NF-ŒB–mediated tran-
scription. Using gene expression and synthetic peptide arrays
on membrane support and overlay analyses, we found here that
inhibiting USP7 increases NF-ŒB ubiquitination and degrada-
tion, prevents Toll-like receptor–induced pro-inflammatory
cytokine expression, and represents an effective strategy for
controlling inflammation. However, the broad regulatory roles
of USP7 in cell death pathways, chromatin, and DNA damage
responses limit the use of catalytic inhibitors of USP7 as anti-
inflammatory agents. To this end, we identified anNF-ŒB–bind-
ing site in USP7, ubiquitin-like domain 2, that selectively
mediates interactions of USP7 with NF-ŒB subunits but is dis-
pensable for interactions with other proteins. Moreover, we
found that the amino acids 757LDEL760 in USP7 critically con-
tribute to the interaction with the p65 subunit of NF-ŒB. Our
findings support the notion that USP7 activity could be poten-
tially targeted in a substrate-selective manner through the de-
velopment of noncatalytic inhibitors of this deubiquitinase to
abrogate NF-ŒB activity.
The transcription factor NF-ŒB is a master regulator of
inflammation and is essential for the development and homeo-
stasis of the immune system. It is activated by most immunore-
ceptors including Toll-like receptors (TLRs), antigen receptors
andmembers of the tumor necrosis factor receptor superfamily
(1). As a consequence, NF-ŒB is critically important for the
transcriptional response to infection and the development of
immunity, and at least 500 genes are direct transcriptional tar-
gets of NF-kB including cytokines, chemokines, regulators of
antigen presentation and cell adhesion, as well as genes that
control cell survival, proliferation, and differentiation (1). The
functional nature of these transcriptional targets makes NF-kB
a central factor in the pathology of a number of important
human diseases including chronic inflammatory disease (e.g.
arthritis, autoimmunity), atherosclerosis, cancer, and neurode-
generation (1). In many of these diseases NF-ŒB is inappropri-
ately activated or active at elevated levels, establishing it as a
factor with significant therapeutic potential.
NF-ŒB is in fact a family of transcription factors formed by
the dimerization of five subunits; RelA (p65), c-Rel, RelB, p50,
and p52. In resting cells, NF-kB is sequestered in the cytoplasm
through interaction with the inhibitor of NF-kB (IkB) proteins,
of which IkBa is the archetypal member. Activation of the IŒB
kinase (IKK) complex (which contains the IKKa and IKKb ki-
nases and the scaffold protein NEMO) leads to IkBa degrada-
tion and the nuclear translocation of NF-kB. Once in the nu-
cleus, NF-kB binds to specific DNA sequences (ŒB sites) to
promote transcription (1). The primary mechanism for termi-
nating NF-kB activity is a negative feedback loop involving NF-
kB–directed resynthesis of IkBa, which relocates NF-kB from
the nucleus to the cytoplasm. There is also a critical IkBa-inde-
pendent mechanism to limit NF-kB activity that requires the
ubiquitination and proteasomal degradation of NF-kB itself
(2–4). Ubiquitination of NF-kB occurs in the nucleus and
depends on the binding of NF-kB to DNA (2, 5). NF-kB ubiqui-
tination is predominantly composed of K48-linked polyubiqui-
tin chains that trigger proteasomal mediated degradation, lead-
ing to reduced NF-kB promoter occupancy and inhibition of
transcription (4). The ubiquitination of NF-ŒB with nondegra-
dative ubiquitin linkages has also been described (6); however,
at present the functional consequences, if any, are unknown. At
least six different E3 ligases for NF-kB have been identified that
appear to regulate NF-kB transcriptional activity in a gene
selective manner (4, 7–12). The apparent nonredundant roles
for these E3 ligases in the regulation of NF-ŒB suggest a com-
plex mechanism for the control of NF-ŒB transcriptional activ-
ity by ubiquitination, which remains largely undefined.
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The importance of ubiquitination in regulating NF-ŒB tran-
scriptional activity was fully recognized following the identifi-
cation of USP7 (ubiquitin-specific protease 7) as a deubiquiti-
nase of NF-kB (13). USP7 directly counteracts the activity of E3
ligases by removing polyubiquitin chains from NF-kB, thereby
stabilizing NF-ŒB and promoting the transcription of target
genes (13). Blocking USP7-mediated deubiquitination of NF-
ŒB inhibits NF-ŒB transcriptional activity while inhibiting the
E3 ligases of NF-ŒB or the proteasome leads to increased tran-
scription of NF-ŒB target genes (4). Thus, the transcriptional
activity of NF-kB is determined by a balance of ubiquitination
and deubiquitination. E3 ligases and USP7 target DNA-bound,
transcriptionally active NF-kB and do not control the upstream
activation of NF-ŒB. As such, the ubiquitination of NF-ŒB rep-
resents an unexploited avenue for the therapeutic control of
inflammatory disease.
We previously demonstrated that the inhibition of USP7
leads to the inhibition of NF-ŒB directed transcription of pro-
inflammatory cytokines such as Il1b, Tnf, and Il6, identifying
USP7 as a potential therapeutic target in inflammatory disease
(13). However, USP7 deubiquitinates a growing number of sub-
strate proteins, many with important roles in the regulation of
key cellular processes such as cell cycle, differentiation, apopto-
sis, DNA replication, and transcription (14, 15). Indeed, the im-
portance of two USP7 substrates in cancer, p53 and MDM2,
has led to significant efforts to develop USP7 inhibitors. The
currently available small molecule inhibitors of USP7 target the
catalytic activity of USP7 and thus inhibit the activity of USP7
against all its substrates including p53, MDM2, and NF-ŒB
(16). Although the impact of USP7 inhibitors on both cell sur-
vival (NF-ŒB) and cell death (p53/MDM2) pathways is desira-
ble in the context of cancer therapy, such broad activity is
unlikely to be beneficial in an anti-inflammatory agent.
In this study, we map the regions of USP7 involved in
the interaction with the p65 (RelA) subunit of NF-ŒB, using
peptide array technology, molecular modeling, and mutagene-
sis approaches. We identify the ubiquitin-like (Ubl) domain 2
of USP7 as critical for the interaction and deubiquitination of
p65 but dispensable for the interaction of USP7 with the USP7
substrates p53, DAXX, and EBNA1. The Ubl2 domain of USP7
is also required for interaction with the c-Rel subunit but not
the RelB subunit of NF-ŒB. Of note, we find the Ubl2 domain of
USP7 is not required for USP7-mediated deubiquitination of
RelB. The findings described here suggest that targeting nonca-
talytic domains of USP7 may enable substrate-selective inhibi-
tion of USP7 activity. Toward this goal we further describe a p65-
binding site in the Ubl2 domain of USP7 that may facilitate the
selective inhibition of USP7-mediated deubiquitination of p65.
Results
USP7 inhibition selectively inhibits TLR-induced NF-ŒB target
gene expression
Wehave previously demonstrated that USP7 deubiquitinates
NF-ŒB p65 to promote NF-ŒB transcriptional responses
induced by tumor necrosis factor a and TLR ligands (13). Our
earlier studies showed that inhibition of USP7 by the small mol-
ecule inhibitor HBX41,108 or siRNA knockdown blocked the
expression of key inflammatory cytokines including Tnf and Il6
(13). To further characterize the impact of USP7 inhibition on
TLR-induced transcriptional responses, we performed a micro-
array-based transcriptomic analysis of murine bone marrow–
derived macrophages (BMDMs) stimulated with the TLR4
ligand lipopolysaccharide (LPS) in the presence or absence of
the USP7 inhibitor HBX41,108 (17). Hierarchical clustering
analysis of LPS-induced genes demonstrated that the USP7 in-
hibitor reduced the expression of a significant number of TLR-
inducible genes in macrophages (Fig. 1A), including the NF-ŒB
target genes encoding inflammatory cytokines Tnf, Il6, Il1b,
and Il12b (Fig. 1B). To further investigate the impact of USP7
inhibition on NF-ŒB–mediated TLR-induced transcriptional
responses, we next analyzed the promoter sequences of genes
inhibited by USP7 inhibitor treatment for the enrichment of
transcription factor–binding sites. This analysis revealed a sig-
nificant over-representation of NF-kB–binding sites in TLR-in-
ducible genes inhibited by USP7 inhibitor treatment (Fig. 1C).
These promoter regions were also enriched in binding sites for
PU.1 and interferon response factors, transcription factors that
cooperate with NF-ŒB to promote the expression of pro-
inflammatory genes (Table S1). These data demonstrate that
USP7 inhibition is an effective approach to block NF-ŒB–medi-
ated inflammatory responses. However, the expanding list of
identified USP7 substrates means that the inhibition of UPS7
catalytic activity will not achieve a selective effect on NF-ŒB ac-
tivity. Instead, strategies that inhibit USP7 activity in a sub-
strate-specific manner are required, which necessitates a
detailed analysis of the recognition of p65 by USP7.
The Ubl2 domain of USP7 is required for interaction with NF-
ŒB p65
Our previous studies revealed that the C-terminal region of
USP7, containing five Ubl domains, is essential for interaction
with p65, whereas the N-terminal MATH domain is dispensa-
ble (13) (Fig. 2A). To further define the C-terminal regions of
USP7 that mediate interaction with p65, we next assessed the
contribution of specific Ubl domains of USP7. To do this, we
generated a series of USP7 mutants in which each of the five
Ubl domains were deleted either individually or in combination
(Fig. 2B). Immunoprecipitation assays using whole cell lysates
from cells co-transfected with p65 revealed that the Ubl5, Ubl4,
and Ubl3 domains of USP7 were dispensable for interaction
with p65. Thus, the deletion of Ubl5, Ubl4, and Ubl3 either
individually or together did not prevent the interaction of USP7
with p65 (Fig. 2, C and D). Deletion or mutation of the linker
region between Ubl3 and Ubl4 also did not prevent interaction
with p65 (Fig. 2E). Furthermore, the deletion of Ubl1 did not in-
hibit USP7 interaction with p65 (Fig. 2F). However, deletion of
Ubl2, either alone or in combination with the deletion of Ubl3,
Ubl4, and Ubl5, prevented the interaction of USP7 with p65
(Fig. 2, C and F). These data demonstrate that the Ubl2 domain
of USP7 is essential for the interaction with p65.
Selective requirement for Ubl2 in USP7 substrate interactions
To determine the contribution of the Ubl2 domain to the
interaction of USP7 with other substrates, we next assessed USP7
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binding to selected substrates by immunoprecipitation assays
using cells transfected with a mutant of USP7 lacking Ubl2
(USP7DUbl2). The results of these experiments demonstrated
that the deletion of Ubl2 did not inhibit the interaction of USP7
with p53 or EBNA1 (Fig. 3, A and B). These findings support pre-
vious studies indicating that the N-terminal MATH domain of
USP7mediates interaction with p53 and EBNA1 (18, 19).We also
tested the ability of USP7DUbl2 to interact with DAXX, a sub-
strate for which the contribution of the C-terminal of USP7 to the
interaction is unknown (20). Similar to p53 and EBNA1, immuno-
precipitation experiments using cells co-transfected with DAXX
and USP7DUbl2 revealed that the deletion of Ubl2 did not affect
the interaction of USP7 and DAXX (Fig. 3C). In similar experi-
ments, we also tested the requirement for Ubl2 in the interaction of
USP7 with the NF-ŒB subunits c-Rel and RelB, which share signifi-
cant sequence and structural homology with p65. This revealed
that, similar to p65, the interaction of c-Rel with USP7 requires the
Ubl2 domain of USP7 (Fig. 3D). Remarkably, however, and in con-
trast to c-Rel and p65, the deletion of Ubl2 did not inhibit the inter-
action ofUSP7with RelB (Fig. 3E). These data demonstrate that the
Ubl2 domain of USP7 is selectively required for the interaction of
USP7 with its substrates, including among homologous members
of theNF-ŒB family of transcription factors.
We previously demonstrated that p65 is a direct substrate of
USP7 and that interaction of p65 with USP7 is required for
USP7-mediated deubiquitination of p65 (13). We next tested
the ability of USP7DUbl2 to deubiquitinate p65 and RelB in an
in-cell ubiquitination assay. The cells were transfected with
HA-tagged ubiquitin, WT USP7 or USP7DUbl2, and RelB or
p65. Following denaturing lysis, RelB or p65 were immunopre-
cipitated and immunoblotted with anti-HA antibody. This
analysis revealed that WT USP7 but not USP7DUBL2 deubi-
quitinated p65 (Fig. 4A), consistent with the inability of
USP7DUbl2 to interact with p65 (Fig. 3). In contrast, both WT
USP7 and USP7DUbl2 were able to deubiquitinate RelB, dem-
onstrating that Ubl2 is dispensable for USP7 interaction with
and deubiquitination of RelB (Fig. 4B).
Analysis of USP7 and NF-ŒB p65 binding by peptide array
Following the identification of the Ubl2 domain as essential
for the interaction of USP7 with p65, we next sought to further
define the specific regions of USP7 that mediate interaction
with p65. To do this we employed a peptide array–based
approach in which an immobilized peptide library representing
the C-terminal region of USP7 was probed with purified
recombinant GSH S-transferase (GST)–p65 protein. Specifi-
cally, a library of overlapping peptides 18 amino acids in length
representing the C-terminal region of USP7 (amino acids 541–
1102) was synthetic peptide arrays on membrane support
(SPOT)–synthesized on nitrocellulose membranes to generate
USP7 C-terminal arrays (Fig. 5A). The peptide arrays were
overlaid with purified recombinant GST or GST-p65 protein,
and interaction with specific peptides was detected using anti-
GST antibody as previously described (21). This analysis
revealed a distinct set of peptides that interacted strongly with
GST-p65 but not GST. These peptides corresponded to
sequences in each of the Ubl1, Ubl2, Ubl3, Ubl4, and Ubl5
domains of USP7, indicating potentially broad contacts with
p65 across the C-terminal of USP7 (Fig. 5, B andC).
Figure 1. USP7 inhibition selectively inhibits LPS-induced expression of NF-ŒB target genes. Murine bone marrow–derived macrophages were stimu-
lated with LPS (100 ng/ml) with or without 30 min of pretreatment with the USP7 inhibitor HBX14,108 (USP7i) (10 mM), and gene expression was analyzed by
microarray. A, hierarchical clustering shows selective inhibition of LPS-induced gene expression by USP7 inhibitor treatment. The heat map displays differen-
tially expressed genes (p.adj, 0.05) scaled as per z score. The values shown are the mean of duplicate samples analyzed. B, box and whisker plots of microar-
ray data for Tnf, Il6, Il1b, and Il12b. C, the promoter regions of 1008 genes (transcriptional start site 6 2000 bp) inhibited by USP7 inhibitor treatment were
analyzed for the occurrence of transcription factor–binding sites using HOMER. These genomic regions were significantly enriched in motifs corresponding to
NF-ŒB–binding sites. Shown are sequence logos for the identified NF-ŒBmotifs and their associated p values.
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To identify specific amino acids within the identified regions
of USP7 that may be important for interaction with p65, we
next generated alanine-scanning arrays of selected peptides
representing each Ubl domain and the C-terminal peptide
region (Fig. 5A). The peptides in these arrays were modified
such that successive amino acids were individually substituted
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with alanine and differed from the parent peptide by one amino
acid. As before, peptide arrays were incubated with GST-p65,
and binding was calculated with respect to the unmodified par-
ent peptide contained on the same array. Substitutions with
less than 60% binding of the parent peptide were considered as
important amino acids formediating the interaction of the pep-
tide with p65. These data identified individual amino acids in
each peptide that were required for interaction with p65. Of
note, the individual substitution of four consecutive amino
acids (LDEL) in a peptide representing amino acids 753–770
(753LDKALDELMDGDIIVFQK770) within the Ubl2 domain of
USP7 blocked interaction with p65 (Fig. 6A). This identified the
757LDEL760 motif of USP7 as a potential binding site for p65. In
addition, the alanine substitution of individual amino acids
in peptides representing regions of USP7 in the other Ubl
domains of the C-terminal protein region were also found to in-
hibit interaction with p65 (Fig. 6, A and B). This included a
large number of amino acids in peptides corresponding to
the Ubl3 domain, as well as the C-terminal peptide region.
Although the data from experiments using USP7 mutants lack-
ing individual Ubl domains showed that these domains are not
essential for the interaction of USP7 with p65 (Fig. 3), it is possi-
ble that potential sites of interaction in these domains may also
contribute to the interaction with p65, perhaps through stabili-
zation of already bound p65.
Lys757, Asp758, Glu759, and Lys760 mediate interaction of USP7
with p65
The alanine-scanning peptide array analysis identified USP7
amino acids Lys757, Asp758, Glu759, and Lys760 (757LDEL760) as
residues that may mediate interaction of USP7 with p65. To
investigate this we mutated these amino acids in USP7 and
assessed the binding to p65 using immunoprecipitation assays.
The cells were co-transfected with p65 and WT USP7 or a
L757A, D758R, E759R, and L760A USP7 mutant, prior to
immunoprecipitation using anti-p65 antibody and subsequent
analysis by immunoblotting. The results of these experiments
revealed that the mutation of Lys757, Asp758, Glu759, and Lys760
of USP7 significantly reduced interaction with p65 (Fig. 6A).
Thus, these data identify a p65-binding site involving residues
757–760 of USP7 that mediates the selective binding to p65.
Discussion
The importance of NF-ŒB in the regulation of pro-inflamma-
tory gene expression has established it as a therapeutic target of
significant potential (22). Previous strategies to inhibit NF-ŒB
function focused largely on the development of inhibitors of
the IKK kinases, key activators of theNF-ŒB pathway. Although
the development of selective inhibitors of the IKK kinases was
successful, their therapeutic use was precluded because of
severe toxicity in early trials, possibly arising from the NF-ŒB–
independent functions of the IKK kinases (23). Thus, the thera-
peutic potential of the NF-ŒB pathway remains untapped, and
alternative approaches beyond inhibiting the IKK kinases are
required.
The ubiquitin-triggered proteasomal degradation of the NF-
ŒB subunits is an important mechanism for the termination of
NF-ŒB transcriptional activity (13). The level of NF-ŒB–
directed pro-inflammatory gene transcription is dictated by the
balance between the action of NF-ŒB E3 ligases and the NF-ŒB
deubiquitinase USP7. The inhibition of USP7 leads to enhanced
ubiquitination and proteasomal degradation of NF-ŒB p65,
resulting in the inhibition of pro-inflammatory gene expression
(13). Here, we have performed the first transcriptomic analysis
of the consequences of USP7 inhibition in macrophages stimu-
lated with the TLR4 ligand LPS. This analysis reveals a signifi-
cant and selective inhibition of NF-ŒB target gene expression
following TLR4 activation and strongly supports the inhibition
Figure 2. The Ubl2 domain of USP7 is required for interaction with p65. A, schematic representation of USP7 mutations used to test interaction with p65.
USP7 contains an N-terminal MATH domain, a central catalytic domain (CD), and five C-terminal Ubl domains. B–F, HEK293T cells were transfected with p65
and the indicated FLAG-tagged USP7 plasmids. USP7 was immunoprecipitated (IP) fromwhole cell lysates using anti-FLAG antibody and analyzed byWestern
blotting (WB) with anti-p65 antibody. The expression of p65 and USP7 in lysates used for immunoprecipitation (input) was measured by Western blotting
using anti-FLAG and anti-p65 antibodies. Western blotting of inputs with anti–b-actin was used to verify equal protein loading. The positions of molecular
mass markers are indicated to the right of eachWestern blot. The data are representative of at least three independent experiments.
Figure 3. The Ubl2 domain of USP7 is required for interaction with c-Rel
but not for interaction with p53, EBNA1, DAXX, or RelB. HEK293T cells
were transfected with the indicated expression plasmids and whole cell
lysates immunoprecipitated (IP) with anti-FLAG (A), anti-HA (B), anti-DAXX
(C), anti-c-Rel (D), or anti-RelB (E). The expression of USP7-FLAG, USP7DUbl2-
FLAG, p53, EBNA1-HA-FLAG, DAXX-FLAG, c-Rel-FLAG, and RelB-FLAG in
whole cell lysates used for immunoprecipitations (input) was measured by
Western blotting (WB) analysis with the indicated antibodies. The positions
of molecular mass markers are indicated to the right of each Western blot.
The data are representative of at least three independent experiments.
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of USP7 deubiquitination of NF-ŒB as a potential therapeutic
strategy.
Although the importance of USP7 in promoting NF-ŒB–
mediated inflammatory responses is clear (13), targeting
USP7 catalytic activity is unlikely to succeed where IKK
inhibitors have failed. This is because, like the IKK kinases,
USP7 has numerous substrates with important roles in a
broad range of cellular processes, including cell cycle, DNA
damage repair, and cell death. Instead, the therapeutic ex-
ploitation of USP7 control of NF-ŒB will require a substrate-
selective approach. The data in this study represent a first
step toward this goal. A p65 mutant that does not bind USP7
is hyperubiquitinated, has a shorter t1/2, and has signifi-
cantly reduced transcriptional activity (13). Thus, interfer-
ing with USP7 and p65 interaction can achieve a substrate-
selective inhibition of UPS7 mediated activity to inhibit the
expression of pro-inflammatory genes. Our previous work
identified the C-terminal domain of USP7 as a critical region
required for interaction with p65 (13). In this study, we have
further defined the Ubl2 domain of USP7 as essential for the
interaction of USP7 with p65. In addition, we find that the
Ubl2 domain is also essential for the interaction of USP7
with the c-Rel subunit of NF-ŒB but not the closely related
RelB subunit. The finding that different domains of USP7
are important for the recognition of related substrates such
as the NF-ŒB subunits is unexpected and suggests that sub-
strate recognition by USP7 likely occurs through diverse
interfaces, even among structurally related proteins. Of
note, our data also show that the Ubl2 domain of USP7 is
not required for the deubiquitination of RelB by USP7, sug-
gesting that the Ubl2 domain functions primarily in sub-
strate recognition rather than contributing to catalytic activity.
Previous studies have shown the Ubl2 domain to be important
for USP7 interaction with ICP0, UHRF1, and DHX40 (18, 24, 25),
whereas the Ubl1 domain is essential for USP7 interaction with
RNF168 (26). A number of USP7 substrates do not require the C-
terminal of USP7 for interaction, including MDM2, p53, and
EBNA1 (18). Indeed, a recent proteomics-based screen to identify
USP7-interacting proteins revealed that most interactions ana-
lyzed occurred through the N-terminal MATH domain of USP7
(25). Together with this study, these data indicate that targeting
USP7–substrate interactions may allow for the selective inhibi-
tion of USP7 activity.
Within the Ubl2 domain, we have identified the amino acids
757LDEL760 as important contributors to the interaction with
p65. These residues may form part of a p65-binding pocket
within the Ubl2 of USP7 that is important for the interaction
with p65. This binding site is adjacent to, but distinct from, a
binding site for UHRF1, IPC0, and GMPS formed by amino
acids 761MDGD764. These studies, together with the data pre-
sented here, suggest that targeting the p65-specific binding site
in USP7 may allow for the inhibition of p65 deubiquitination,
leading to increased proteasomal degradation and reduced
transcriptional activity, without broadly affecting the activity of
USP7 toward all substrates. Similar approaches to mapping
other substrate interaction sites of USP7may lead to the identi-
fication of additional binding pockets that may be selectively
targeted to achieve substrate-selective inhibition of USP7-
mediated deubiquitination. Such an understanding of USP7
substrate interactionmay facilitate the selective targeting of dif-
ficult to drug proteins such as NF-ŒB and other transcription
factors.
Figure 4. The Ubl2 domain is required for USP7 deubiquitination of p65 but not RelB. HEK293T cells were transfected with HA-tagged ubiquitin, USP7,
USP7DUbl2, and p65 (A) or RelB (B). Denatured whole cell lysates were immunoprecipitated with anti-p65 (A) or anti-RelB (B) and analyzed byWestern blotting
(WB) with anti-HA antibody and anti-p65 (A) or anti-RelB (B) antibody. The expression of transfected USP7, USP7DUbl2, p65, and RelB in lysates used for immu-
noprecipitations (IP, input) was measured byWestern blotting using antibodies against USP7, p65, and RelB. The positions of molecular mass markers are indi-
cated to the right of eachWestern blot. The data are representative of at least three independent experiments.
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Cell culture, plasmids, and transfection
Human embryonic kidney 293T (HEK293T) cells were cul-
tured in high-glucose Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% heat-inactivated fetal bovine serum, 2
mM glutamine, and 100 units/ml penicillin/streptomycin. Mu-
rine BMDMs were generated as previously described (5). Briefly,
bone marrow was isolated from age- and sex-matched C57BL6/J
mice at 8–12 weeks old and cultured in bacterial Petri dishes with
DMEM containing 10% fetal bovine serum, 2 mM glutamine, and
100 units/ml penicillin/streptomycin supplemented with 30%
L929 conditioned medium for 7 days, with medium replacement
after 4 days. On day 7, BMDMs were harvested in PBS solution
supplemented with 5mM EDTA and replated into tissue culture–
treated dishes in DMEM without L929 conditioned medium.
Theywere rested overnight, and the experiments were performed
on day 8. The cells weremaintained at 37 °C in a humidified envi-
ronment with 5%CO2. These experiments were carried out in ac-
cordance with the recommendations of the Code of Practice for
the Humane Killing of Animals under Schedule 1 to the United
KingdomAnimals (Scientific Procedures) Act 1986, where excess
tissue was used for isolation of bone marrow cells. Transfections
were performed using Turbofect transfection reagent according
to the manufacturer’s instructions (Fermentas). Mammalian
expression vectors for USP7, p65, c-Rel, RelB, and DAXX were
generated following PCR amplification and ligation of cDNAs
into the pcDNA-FLAG or pRK5-FLAG vectors. MSCV-N
EBNA1 was a gift from Karl Munger (Addgene plasmid 37954).
pCMV-p53 plasmid was purchased from Clontech. pET-42a-
GST-p65 plasmid was generated by gene synthesis (GenScript).
Site-directed mutagenesis was performed using the Q5 site-
Figure 5. Peptide array analysis identifies distinct regions of USP7 Ubl domains with potential for interacting with p65. A, peptide arrays of immobilized
overlapping 18-mer peptides, each shifted to the C terminus by 4 amino acids, encompassing the C-terminal region of USP7 were generated. Peptide identi-
fiers and the corresponding amino acids and domain location in USP7 are shown. B, arrays were probedwith recombinant GST or GST-p65 and detected by im-
munoblotting with anti-GST antibody. Positive GST-p65 binding to USP7 peptides is indicated by black spots. The data shown are representative of duplicate
arrays. Peptide identifiers shown in A are indicated. C, schematic of the C-terminal regions of USP7 showing the location of peptides that interact with p65
identified in the peptide array.
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Figure 6. Identification of amino acids important for USP7 interaction with p65. A, the 18 amino acids of USP7-derived peptides of interest were sequen-
tially substituted with alanine, probed with GST-p65, and detected by immunoblotting with anti-GST antibody. The peptides are labeled according to Fig. 5.
p65 binding was quantified and calculated as a percentage binding of the parent unsubstituted peptide (-) on the same array. Alanine substitutions that
resulted in less than 60% binding are indicated by asterisks. The corresponding USP7 amino acid number for first residue of each peptide is shown above each
individual substitution peptide series. B, the structure of each Ubl domain with amino acids identified by alanine-scanning experiments indicated in red. The
images were generated using Protein Data Bank structure 2YLM. C, HEK293T cells were transfected with p65 and FLAG-tagged USP7, USP7 mutated at resi-
dues 757–760, and USP7 lacking the Ubl2 domain (USP7DUbl2). p65 was immunoprecipitated (IP) from whole cell lysates using anti-p65 antibody and ana-
lyzed by Western blotting (WB) with anti-FLAG antibody. The expression of p65 and USP7 in lysates used for immunoprecipitation (input) was measured by
Western blotting using anti-FLAG and anti-p65 antibodies. The positions of molecular mass markers are indicated to the right of eachWestern blot.
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directedmutagenesis kit according to themanufacturer’s instruc-
tions (New England Biolabs).
Gene expression analysis
Total RNA was isolated using the RNeasy mini kit (Qiagen)
with DNase treatment. RNA quantification and purity were
measured using the Nanodrop ND1000 spectrophotometer
(Thermo Scientific), with samples submitted for microarray
profiling (Beckman Coulter Genomics, Morrisville, NC). Briefly,
200 ng of total RNA was fluorescently labeled with Cy3 nucleo-
tides. Labeled RNA (cRNA) was hybridized to Agilent mouse
8X60K mouse microarrays (Agilent-028005). Hybridized arrays
were washed and scanned, with data extrapolated for down-
stream bioinformatics analysis. Microarray gene-expression
profiling was performed in duplicate. The data were normalized
using Limma (3.38.3), including quantile normalization (27). A
linear model was fitted to identify differentially expressed probes
using an adjusted p value (Benjamini and Hochberg) of 0.05. The
data are available at the NCBI Gene Expression Omnibus
(GSE149478). Transcription factor–binding site analysis was per-
formed usingHOMER (RRID:SCR_010881).
Bacterial protein expression and purification
For purification of recombinant GST-p65, Escherichia coli
BL21 DE3 (Agilent Technologies) were transformed with pET-
42a-GST-p65. The cultures were induced with 0.5 mM isopro-
pyl b-D-1-thiogalactopyranoside and incubated for 3 h with
shaking (150 rpm) at 37 °C. The bacteria were resuspended in
buffer containing 50 mM Tris (pH 8.5), 150 mM NaCl, and 10
mM DTT, disrupted by sonication, and centrifuged to remove
debris. GST-p65 was purified using GSH–agarose (Sigma) and
eluted in buffer containing 50mM Tris (pH 8), 10 mMDTT, and
10mM reduced GSH (Promega).
SPOT synthesis of peptides and overlay analysis
Peptide libraries of USP7 were generated by automatic SPOT
synthesis as previously described (21). The interaction of GST
and GST-p65 proteins with the peptide array was investigated
by overlaying the peptide array membrane with 10 mg/ml of
each protein overnight at 4 °C. Bound GST-p65 was measured
by immunoblotting with anti-GST antibody (Sigma) and anti-
rabbit horseradish peroxidase–conjugated secondary antibody
(GE Healthcare) prior to enhanced chemiluminescence (ECL)
detection. Specific alanine-scanning arrays were generated
using the same procedure, and bound protein was detected and
quantified using a digital chemiluminescence scanner (LiCor).
Western blotting analysis and immunoprecipitation
For Western blotting analysis, whole cell lysates were pre-
pared from cells suspended in radioimmune precipitation assay
(RIPA) buffer containing 50mM Tris-HCl (pH 7.4), 0.1–1% Ige-
pal, 0.25% deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, 1 mM NaF, 1 mM Na3VO4, 2 mg/
ml aprotinin, 1 mg/ml pepstatin, and 1 mg/ml leupeptin. Lysates
were resolved on SDS-PAGE gels and transferred to nitrocellu-
lose, and membranes were immunoblotted with specific
antibodies. Anti-p65 was obtained from Santa Cruz Biotech-
nologies (sc-80089 and sc-372) and Bethyl Laboratories (A301-
824A); anti-USP7 was obtained from Bethyl Laboratories
(A300-033A); and Santa Cruz Biotechnologies provided anti-
p53 (sc-6243), anti-HA (sc-805), anti-c-Rel (sc-71), anti-DAXX
(sc-7152), and anti-RelB (sc-226) antibodies. Anti-FLAG
(F1804), anti-GST (G7781), and anti–b-actin (SAB 1305567)
antibodies were supplied by Sigma. For immunoprecipitation,
equal amounts of whole cell extracts were precleared for 30
min at 4 °C with protein G–agarose beads (Millipore) and
immunoprecipitated with specific antibody overnight at 4 °C.
The beads were washed three times in RIPA buffer and eluted
by boiling in 23 sample buffer (100 mM Tris, pH 6.8, 20% glyc-
erol, 4% SDS, 0.2% bromphenol blue, 200 mM b-mercaptoetha-
nol). Equal volumes of eluted immunoprecipitates were ana-
lyzed by Western blotting. Ubiquitination assays were carried
out as previously described (5). Briefly, the cells were incubated
with 10 mM N-ethylmaleimide for 30 s and washed in PBS sup-
plemented with 10 mM N-ethylmaleimide. The cells were lysed
in 1% SDS, boiled for 5 min, and sonicated. Cleared lysates were
diluted 1:10 in RIPA buffer supplemented with 20 mM N-ethyl-
maleimide. Immunoprecipitation was performed as above and
analyzed byWestern blotting to detect ubiquitinated protein.
Data availability
Themicroarray data presented have all been deposited in the
NCBI GEO database with the following accession number:
GSE149478. All remaining data are contained within the
article.
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